OHSU in the news

AD Outcomes Improved With Lebrikizumab and Topical Steroids

Medscape January 13, 2023
New research led by Eric Simpson, M.D., revealing adults and adolescents with moderate to severe atopic dermatitis showed significant improvements with the addition of lebrikizumab to topical steroid therapy compared to TCS plus placebo.

Lipid Nanoparticle Technology May Advance Gene Therapy for Blindness

Inside Precision Medicine January 12, 2023
OHSU and Oregon State University researchers are developing a new approach to gene therapy for inherited forms of blindness that uses lipid nanoparticles to deliver gene-altering mRNA. Renee Ryals, Ph.D., says: “Improving the technologies used for gene therapy can provide more treatment options to prevent blindness. Our study’s findings show that lipid nanoparticles could help us do just that.”

Nanotechnology may improve gene therapy for blindness

Innovations Report January 12, 2023
OHSU and Oregon State University researchers are developing a new approach to gene therapy for inherited forms of blindness that uses lipid nanoparticles to deliver gene-altering mRNA. Renee Ryals, Ph.D., says: “Improving the technologies used for gene therapy can provide more treatment options to prevent blindness. Our study’s findings show that lipid nanoparticles could help us do just that.”

Nanotechnology may improve gene therapy for blindness

Nano Magazine January 12, 2023
OHSU and Oregon State University researchers are developing a new approach to gene therapy for inherited forms of blindness that uses lipid nanoparticles to deliver gene-altering mRNA. Renee Ryals, Ph.D., says: “Improving the technologies used for gene therapy can provide more treatment options to prevent blindness. Our study’s findings show that lipid nanoparticles could help us do just that.”

XBB.1.5 on its way to being predominant COVID-19 subvariant

Oregon Health News January 12, 2023
Xuan Qin, Ph.D., and Bill Messer, M.D., Ph.D., are quoted in an OHA Oregon Health News post about XBB.1.5 on its way to becoming the predominant COVID-19 subvariant in Oregon. Qin says, “This new subvariant is a perfect example of how the SARS-CoV-2 virus is capable of adapting to selective pressure through mutations and re-combinations with earlier variants.”

OHSU doctor urges Oregonians to carry Narcan amid fentanyl overdose spike

KOIN-TV January 12, 2023
In a KOIN story about the increase in fentanyl overdoses in Oregon, Bradley Buchheit, M.D., says, “Everyone should be carrying and know how to use naloxone … Over the past few years within the state of Oregon, we’ve seen a dramatic change in our drug supply. We went from seeing black tar heroin in the drug supply to now almost all fentanyl -- which is about 50 times as potent as morphine.” Interview initially conducted as part of a special hourlong segment that aired in December. See OHSU News stories about the importance of naloxone and a roundtable discussion about the danger fentanyl presents to young people.

OR Health System to Test AI App That Tracks Blood Sugar Levels

Health IT Analytics January 12, 2023
Peter G. Jacobs, Ph.D., and Leah M. Wilson, M.D., are organizing a clinical trial to evaluate how well patients can better manage their type 1 diabetes with the help of their artificial intelligence-powered app and the support of human experts in diabetes and behavioral health.

Ted Chaiban on vaccinating the world

POLITICO January 11, 2023
In a Politico story about new research led by Jane Zhu, M.D., revealing changes in the health care workforce after physician-owned practices are acquired by private equity, she says, “We’re facing huge changes in the practice environment. … The data that we know about in the industry reports are suggesting that [private equity] growth in health care has only increased during Covid, not decreased.”
See more stories